A more recent report on CLL patients with dual resistance to BTK inhibition and Bcl-2 antagonism has identified emerging BCL2 mutations in 4 out of 11 cases, with only 2 characterized by a mutated cancer cell fraction above 25% [63]. This evidence concerns the gene BTK and cancer.